{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-98.77","upperLimit":"327.76","value":"-37.42"},{"groupId":"OG001","lowerLimit":"-96.88","upperLimit":"70.56","value":"-71.19"},{"groupId":"OG002","lowerLimit":"-99.5","upperLimit":"192.1","value":"-55.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"30"},{"groupId":"OG001","value":"31"},{"groupId":"OG002","value":"33"}],"units":"Participants"}],"description":"Best percentage change in cancer antigen 125 (CA-125) levels","dispersionType":"Full Range","groups":[{"description":"Olaparib (AZD2281) 200 mg oral capsules twice daily","id":"OG000","title":"Olaparib 200 mg bd"},{"description":"Olaparib (AZD2281) 400 mg oral capsules twice daily","id":"OG001","title":"Olaparib 400 mg bd"},{"description":"Liposomal doxorubicin 50 mg/m2 intravenously every 4 weeks","id":"OG002","title":"Liposomal Doxorubicin"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"At the time that 57 PFS events had occurred (Data cut-off for primary analysis of PFS: 15 September 2009)","title":"Best Percentage Change From Baseline in CA-125 Levels","type":"SECONDARY","unitOfMeasure":"Percent change"}